At Moscow ceremony of awarding the winners of prestigious all-Russian Beauty Award “Crystal Lotus”, NPO Microgen’s flagship product, the first Russian Relatox® Botulinum toxin type A, was recognized the best in the nomination “Best Premium Class Prescription Drug".
“We are happy to receive the award and recognition of professional community. Currently, we note a great interest in our brand both from the side of specialists and customers, and receive a great number of positive feedback for the drug quality. After 7 years of successful use of Relatox® in the market, we earned the trust of the most demanding experts. This award is the acknowledgment of the fact that we develop our product moving in the right direction,” Elena Pavlovna Shirokova, Head of the marketing department, said.
Relatox® Botulinum toxin type A is an innovative drug fully developed and produced in Russia. It came through all phases of clinical trials, having received a high positive assessment from experts and medical practitioners.
Special patented technique of neuroprotein obtainment from Clostridium botulinum 501 serotype A strain, which was independently cultivated and well-studied by Relatox® developers is used in production of the drug. Moreover, in the course of production, a three-step technology of botulinum toxin purification is used providing its highest quality, efficiency and safety of use.
So far, Relatox® worthly competes with foreign botulinum toxins and holds one of the leading market positions according to the results of 10 months of 2020.
Relatox® is efficiently used by many institutions and clinics of aesthetic cosmetology as a reliable and highly efficient method of anti-aging treatment. Cosmetologists and plastic surgeons apply the drug for mimic wrinkles correction in all facial areas using the “Full-Face” technique.
